Olympia Biosciences™

UEMS Medical Specialties · MeSH-Tagged Dossiers · CDMO Science

Therapeutic R&D Intelligence Hub

76 formulation dossiers indexed across UEMS medical specialties and CDMO technology domains — each anchored in peer-reviewed evidence. Select your field below.

⌘K to search any dossier

Smart Search

Find any dossier in seconds

Search by molecule, axis, challenge, category, or MeSH topic.

Try: bioavailability, PCOS, GLP-1, endotoxin, stability.

76

Published Dossiers

11

UEMS Specialties

5

CDMO Technology Domains

125M+

Papers Indexed via Elicit

Newest Research

Latest Publications

Formulation dossiers published most recently, sorted by date.

New

Precision Microbiome & Gut-Brain Axis

Enteric-Targeted Butyrate Delivery for Vagal Nerve Stimulation: Addressing Gastric Degradation and Organoleptic Challenges

Designing oral butyrate formulations is challenged by premature gastric dissolution, proximal absorption, and severe organoleptic issues, preventing effective distal gut targeting and patient adherence.

≈ 23 min read

Butyric Acids Fatty Acids, Volatile
View Dossier
New

Transmucosal Delivery & Dosage Form Engineering

Isomeric Stabilization in High-Moisture Matrices: Manufacturing Controls for Protecting Fixed-Ratio Inositol Formulations

Maintaining precise fixed component ratios in solid oral formulations, especially those involving moisture-sensitive active ingredients like inositol, is challenging due to segregation during processing and moisture-driven changes in material properties. This leads to content uniformity failures and compromised dosing accuracy.

≈ 15 min read

Fixed-Ratio Drug Combinations Drug Stability
View Dossier
New

Glycolysis-Restricted FSMP (Oncology Nutrition)

The Glucose Paradox in Oncology Nutrition: High-Glycemic Medical Foods and Cancer Outcomes

Current sugar-dominant oncology medical foods may inadvertently fuel tumor growth and worsen metabolic dysfunction in cancer patients. Developing nutritionally complete, low-glycemic formulations that support anabolism without pro-oncogenic effects is a critical challenge.

≈ 21 min read

Medical Foods Oncology
View Dossier
New

Female Endocrine-Metabolic Crosstalk

Intrapartum Bioenergetics: Rheological Engineering of a Carbohydrate-Based Hydrogel Matrix to Overcome Delayed Gastric Emptying During Active Labour

Developing a carbohydrate-based oral formulation for active labour presents a challenge: it must rapidly deliver energy and prevent neonatal hypoglycemia without exacerbating delayed gastric emptying, increasing aspiration risk, or inducing maternal/neonatal hyperglycemia.

≈ 13 min read

Gastric Emptying Hydrogels
View Dossier
New

Cerebral Bioenergetics & Neuro-Metabolic Rescue

Ketogenic Interventions in Neurodegeneration: Mechanisms, Clinical Efficacy, and Therapeutic Challenges

Developing clinically robust and compliant ketogenic interventions for neurodegenerative diseases requires overcoming challenges related to variable metabolic responses, sustained therapeutic ketosis, and precise delivery of ketone bodies or precursors in diverse patient populations.

≈ 16 min read

Ketogenic Diet Neurodegenerative Diseases
View Dossier
New

Advanced BBB Permeability Solutions

Lipid Nanoformulations for CNS Delivery of Lipophilic Botanicals: BBB Transport & Catecholaminergic Nootropic Support

Delivering lipophilic botanicals to the central nervous system is hindered by the blood-brain barrier (BBB), rapid metabolism, and low solubility, leading to poor systemic and brain exposure for promising nootropic compounds.

≈ 25 min read

Blood-Brain Barrier Nanoparticles
View Dossier

Alphabetical Reference Index

Complete R&D Dossier Index

76 evidence-based formulation dossiers — click any title to access the full research article.

Evidence-Based Medicine

The Science of Formulation: Our Commitment to Evidence-Based Medicine

At Olympia Biosciences—a premier global Contract Development and Manufacturing Organization (CDMO) proudly rooted in Poland—we believe that world-class health solutions begin with uncompromising scientific rigor. As a dedicated, pure-play B2B partner, we do not own, market, or sell proprietary consumer brands. Our sole mission is to serve as the scientific and operational powerhouse behind the world's elite doctor-led brands and healthcare enterprises that demand the highest standards of quality, safety, and Evidence-Based Medicine (EBM).

Why We Publish Independent Scientific Literature

Behind every formulation we engineer stands a multidisciplinary team of medical doctors, biotechnologists, and research scientists. While we strictly adhere to global regulatory frameworks—routinely equipping our partners with comprehensive, EFSA-compliant claim declarations—we also recognize a fundamental reality of modern healthcare: the pace of clinical discovery frequently outstrips the speed of institutional updates.

We hold the utmost respect for global regulatory authorities, yet for our team, basic compliance is merely the baseline. We proactively analyze emerging clinical and scientific data because we must be absolutely certain that every formulation we develop is fundamentally safe, highly bioavailable, and unequivocally effective within its targeted scope.

The independent medical and scientific reviews published on our platform are general overviews, not tied to any specific commercial product. They reflect our mandate to champion the science that drives the industry forward. By bridging the gap between cutting-edge academic research and commercial manufacturing, Olympia Biosciences empowers your brand to deliver market-leading products defined by genuine scientific integrity.

Shape Our Research Agenda

Didn't find your research topic?

Tell us what formulation science challenge you're working on. We review every suggestion — if we develop the dossier, we'll notify you first. No cost. No commitment. Just science.

✓ Free ✓ Assessed by Olimpia Baranowska ✓ You'll be first to receive the dossier

Your data is used only to notify you when the dossier is published. No marketing emails.

Science Newsletter

New R&D Article Every Week

Get Olimpia's latest therapeutic research insights delivered straight to your inbox. B2B formulators & pharma scientists only.

No spam. Unsubscribe anytime. One email per week.

Our IP Pledge

We do not own consumer brands. We never compete with our clients.

Every formula engineered at Olympia Biosciences™ is built from scratch and transferred to you with full intellectual property ownership. Zero conflict of interest — guaranteed by ISO 27001 cybersecurity and ironclad NDAs.